Dehydroascorbic acid
(Synonyms: 脱氢抗坏血酸) 目录号 : GC33746
An oxidized form of ascorbic acid
Cas No.:490-83-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Dehydroascorbic acid is an oxidized form of ascorbic acid .1 It is obtained through the diet or formed via oxidation of ascorbic acid in the gut and can also be reduced back to ascorbic acid in various cell types. Dehydroascorbic acid (0.5 and 1 mM) inhibits hydrogen peroxide-induced cell death in murine astrocytes by approximately 74 and 83%, respectively.2 It also increases glutathione peroxidase (GPX) and glutathione reductase activity and inhibits production of reactive oxygen species (ROS) in hydrogen peroxide-treated astrocytes when used at a concentration of 1 mM. Dehydroascorbic acid (40 and 250 mg/kg) increases cerebral blood flow and reduces infarct volume and mortality in a mouse model of cerebral ischemia-reperfusion injury induced by transient middle cerebral artery occlusion (MCAO) when administered prior to ischemia.3 It also reduces infarct volume in a permanent MCAO mouse model when administered pre- or post-ischemia at doses of 250 and 500 mg/kg, respectively.
1.Wilson, J.X.The physiological role of dehydroascorbic acidFEBS Lett.527(1-3)5-9(2002) 2.Kim, E.J., Park, Y.G., Baik, E.J., et al.Dehydroascorbic acid prevents oxidative cell death through a glutathione pathway in primary astrocytesJ. Neurosci. Res.79(5)670-679(2005) 3.Huang, J., Agus, D.B., Winfree, C.J., et al.Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental strokeProc. Natl. Acad. Sci. USA98(20)11720-11724(2001)
| Cas No. | 490-83-5 | SDF | |
| 别名 | 脱氢抗坏血酸 | ||
| Canonical SMILES | OC[C@@H]([C@](O1)([H])C(C(C1=O)=O)=O)O | ||
| 分子式 | C6H6O6 | 分子量 | 174.11 |
| 溶解度 | DMSO: 10 mg/ml,DMSO:PBS (pH 7.2) (1:5): 0.16 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.7435 mL | 28.7175 mL | 57.435 mL |
| 5 mM | 1.1487 mL | 5.7435 mL | 11.487 mL |
| 10 mM | 0.5743 mL | 2.8717 mL | 5.7435 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Dehydroascorbic acid
J Chromatogr A 2000 Jun 9;881(1-2):299-307.PMID:10905713DOI:10.1016/s0021-9673(00)00166-7.
Dehydroascorbic acid (DHA) is an important, interesting but somewhat enigmatic compound in biological systems. DHA has many unique properties that set it apart from ascorbic acid (AA), and DHA has functions that may be very important beyond that in the AA:DHA cycle. Future studies should help to better clarify chemical activity of DHA and related products that form from DHA, as well as to highlight the role DHA plays in normal cellular homeostasis.
Topical L-ascorbic acid: percutaneous absorption studies
Dermatol Surg 2001 Feb;27(2):137-42.PMID:11207686DOI:10.1046/j.1524-4725.2001.00264.x.
Background: Reactive oxygen species generated by ultraviolet light result in photocarcinogenic and photoaging changes in the skin. Antioxidants protect skin from these insults. Objective: This study defines formulation characteristics for delivering L-ascorbic acid into the skin to supplement the skin's natural antioxidant reservoir. Methods: L-ascorbic acid or its derivatives were applied to pig skin. Skin levels of L-ascorbic acid were measured to determine percutaneous delivery. Results: L-ascorbic acid must be formulated at pH levels less than 3.5 to enter the skin. Maximal concentration for optimal percutaneous absorption was 20%. Tissue levels were saturated after three daily applications; the half-life of tissue disappearance was about 4 days. Derivatives of ascorbic acid including magnesium ascorbyl phosphate, ascorbyl-6-palmitate, and Dehydroascorbic acid did not increase skin levels of L-ascorbic acid. Conclusions: Delivery of topical L-ascorbic acid into the skin is critically dependent on formulation characteristics.
Dehydroascorbic acid as an anti-cancer agent
Cancer Lett 2008 May 18;263(2):164-9.PMID:18378072DOI:10.1016/j.canlet.2008.02.002.
Three discoveries together point the way to a potential treatment for cancer. In 1982, Poydock and colleagues found that Dehydroascorbic acid has the remarkable ability to eliminate the aggressive mouse tumours, L1210, P388, Krebs sarcoma, and Ehrlich carcinoma. In 1993, Jakubowski found that cancer cells (but not normal cells) contain measurable quantities of homocysteine thiolactone. Recently, the author found that Dehydroascorbic acid reacts with homocysteine thiolactone converting it to the toxic compound, 3-mercaptopropionaldehyde. Taken together, these findings suggest that rapidly-dividing tumour cells make unusually large amounts of homocysteine thiolactone and that administered Dehydroascorbic acid enters the cells and converts the thiolactone to mercaptopropionaldehyde which kills the cancer cells. The effectiveness of Dehydroascorbic acid might be further increased by combining it with methionine and/or methotrexate to increase the homocysteine concentration in cancer cells.
Metabolic control by Dehydroascorbic acid: Questions and controversies in cancer cells
J Cell Physiol 2019 Nov;234(11):19331-19338.PMID:30963581DOI:10.1002/jcp.28637.
For a long time, the effect of vitamin C on cancer cells has been a controversial concept. From Linus Pauling's studies in 1976, it was proposed that ascorbic acid (AA) could selectively kill tumor cells. However, further research suggested that vitamin C has no effect on tumor survival. In the last decade, new and emerging functions for vitamin C have been discovered using the reduced form, AA, and the oxidized form, Dehydroascorbic acid (DHA), independently. In this review, we summarized the latest findings related to the effects of DHA on the survival and metabolism of tumor cells. At the same time, we put special emphasis on the bystander effect and the recycling capacity of vitamin C in various cellular models, and how these concepts can affect the experimentation with vitamin C and its therapeutic application in the treatment against cancer.
Dehydroascorbic acid Affects the Stability of Catechins by Forming Conjunctions
Molecules 2020 Sep 7;25(18):4076.PMID:32906587DOI:10.3390/molecules25184076.
Although tea catechins in green tea and green tea beverages must be stable to deliver good sensory quality and healthy benefits, they are always unstable during processing and storage. Ascorbic acid (AA) is often used to protect catechins in green tea beverages, and AA is easily oxidized to form Dehydroascorbic acid (DHAA). However, the function of DHAA on the stability of catechins is not clear. The objective of this study was to determine the effects of DHAA on the stability of catechins and clarify the mechanism of effects by conducting a series of experiments that incubate DHAA with epigallocatechin gallate (EGCG) or catechins. Results showed that DHAA had a dual function on EGCG stability, protecting its stability by inhibiting hydrolysis and promoting EGCG consumption by forming ascorbyl adducts. DHAA also reacted with (-)-epicatechin (EC), (-)-epicatechin gallate (ECG), and (-)-epigallocatechin (EGC) to form ascorbyl adducts, which destabilized them. After 9 h of reaction with DHAA, the depletion rates of EGCG, ECG, EC, and EGC were 30.08%, 22.78%, 21.45%, and 13.55%, respectively. The ability of DHAA to promote catechins depletion went from high to low: EGCG, ECG, EGC, and EC. The results are important for the processing and storage of tea and tea beverages, as well as the general exploration of synergistic functions of AA and catechins.